Peng Mao

Peng Mao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
WLWen-Hui Liu
Wen-Hui Liu
HHHui-Min Hu
Hui-Min Hu
CLChen Li
Chen Li
QSQing Shi
Qing Shi
CLChun-Hua Liu
Chun-Hua Liu
BFBi-Fa Fan
Bi-Fa Fan
Triptans selectively agoniste 5-Hydroxytryptamine(5-HT) receptors and are widely used in the treatment of migraine. Nevertheless, there is a dearth of comprehensive real-world clinical research on the safety of triptans. In light of the growing prevalence of migraine, it is imperative to gain a deeper understanding of the true extent of adverse events (AEs) associated with triptans in the clinical management of migraine. A database query of AEs reported to the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database for triptans was performed using the online platform Open Vigil 2.1. The query spanned the period from 1 January 2018 to 31 December 2023 and extracted all AEs for ‘sumatriptan’, ‘zolmitriptan’, ‘rizatriptan’, and ‘naratriptan’ from the 15–49 years old population and retrospective quantitative analyses. A proportional reporting ratio (PRR), reporting odds ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN) methodology were utilized to contrast AEs across the four triptans. A total of 1.272 AEs reports for sumatriptan, 114 for zolmitriptan, 162 for rizatriptan, and 15 for naratriptan were identified. The ratio of females to males was approximately three times higher in all cases, with the highest number of reports originating from the Americas. A review of the FAERS database revealed that nervous system disorders were the primary SOC category for four drugs, with all four drugs exhibiting the AE indicative of reversible cerebral vasoconstriction syndrome, also classified as Nervous system disorders. The most frequently reported AE signal for sumatriptan was dyspnea, which is classified as respiratory, thoracic and mediastinal disorders. The most frequently reported AEs signals for the remaining three drugs were nausea, vomiting and terminal ileitis, all of which are classified as gastrointestinal disorders. Analyses have demonstrated that AEs are present in a range of systems, including cardiac, nervous, gastrointestinal, and musculoskeletal disorders. It should be noted, however, that the incidence and signal intensity of these AEs vary depending on the specific drug in question. In clinical practice, the selection of an appropriate drug and the monitoring of AEs should be tailored to the individual patient’s and specific characteristics.

1 August 2021 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
SWShubiao Wu
Shubiao Wu
PMPeng Mao
Peng Mao
RLRizeng Li
Rizeng Li
ZCZhennao Cai
Zhennao Cai
Ali Asghar HeidariAli Asghar Heidari
Ali Asghar Heidari
XCXiaowei Chen
Xiaowei Chen

1 April 2021 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
YHYing Huang
Ying Huang
CXChenjie Xu
Chenjie Xu
TZTao Zeng
Tao Zeng
ZLZhongming Li
Zhongming Li
YXYanzhi Xia
Yanzhi Xia
JLJian Lin
Jian Lin
Ying Huang, Chenjie Xu, Tao Zeng, Zhongming Li, Yanzhi Xia, Gaojian Tao, Tong Zhu, Lijuan Lu, Jing Li, Taiyuan Huang, Hongbo Huai, Benxiang Ning, Chao Ma, Xinxing Wang, Yuhua Chang, Peng Mao, and Jian Lin. Korean J Pain 2021;34:210-6. https://doi.org/10.3344/kjp.2021.34.2.210

21 June 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
WLWenHui Liu
WenHui Liu
HHHuiMin Hu
HuiMin Hu
CLChen Li
Chen Li
YLYiFan Li
YiFan Li
PMPeng Mao
Peng Mao
BFBi-Fa Fan
Bi-Fa Fan
Objective: According to data from several observational studies, there is a strong association between circulating inflammatory cytokines and postherpetic neuralgia (PHN), but it is not clear whether this association is causal or confounding; therefore, the main aim of the present study was to analyze whether circulating inflammatory proteins have a bidirectional relationship with PHN at the genetic inheritance level using a Mendelian randomization (MR) study.Methods: The Genome-Wide Association Study (GWAS) database was used for our analysis. We gathered data on inflammation-related genetic variation from three GWASs of human cytokines. These proteins included 91 circulating inflammatory proteins, tumor necrosis factor-alpha (TNF-α), macrophage inflammatory protein 1b (MIP-1b), and CXC chemokine 13 (CXCL13). The PHN dataset was obtained from the FinnGen biobank analysis round 5, and consisted of 1,413 cases and 275,212 controls. We conducted a two-sample bidirectional MR study using the TwoSampleMR and MRPRESSO R packages (version R.4.3.1). Our main analytical method was inverse variance weighting (IVW), and we performed sensitivity analyses to assess heterogeneity and pleiotropy, as well as the potential influence of individual SNPs, to validate our findings.Results: According to our forward analysis, five circulating inflammatory proteins were causally associated with the development of PHN: interleukin (IL)-18 was positively associated with PHN, and IL-13, fibroblast growth factor 19 (FGF-19), MIP-1b, and stem cell growth factor (SCF) showed reverse causality with PHN. Conversely, we found that PHN was closely associated with 12 inflammatory cytokines, but no significant correlation was found among the other inflammatory factors. Among them, only IL-18 had a bidirectional causal relationship with PHN.Conclusion: Our research advances the current understanding of the role of certain inflammatory biomarker pathways in the development of PHN. Additional verification is required to evaluate the viability of these proteins as targeted inflammatory factors for PHN-based treatments.

1 May 2019 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
YLYi-Fan Li
Yi-Fan Li
PMPeng Mao
Peng Mao
QZQian Zhu
Qian Zhu
BLBo-Tao Liu
Bo-Tao Liu
BFBi-Fa Fan
Bi-Fa Fan
Objective: To report a successful attempt of peripheral nerve field stimulation (PNFS) in preauricular area to treat refractory chronic migraine (CM). This article focuses on novel utilization of PNFS and discusses its existing issues. Case report: A 35-year-old woman diagnosed with CM complained about a 2-year history of severe pain at the occipitocervical and left auriculotemporal area, sometimes bilaterally, which did not benefit from conventional medical therapy. After failed attempts of occipital nerve stimulation and PNFS at the retroauricular area, we used exploratory PNFS at the preauricular area, which to our knowledge is the first reported case in literature, to such an area in refractory CM. The patient experienced satisfactory pain relief and obvious improvement in quality of life. And the amelioration on the severity of pain was validated by reduced scores (from 9 to 2) on the numerical rating scale. The clinical effects continued in the next 2-year follow-up after the implantation, without adverse events. Conclusion: PNFS is a promising and safe neuromodulation therapy for refractory CM. Facial areas like preauricular region are applicable for lead implantation. Nevertheless, the underlying mechanisms are still unverified, and there is still a lack of standardized operation guides of PNFS. Large-scale randomized clinical trials should be conducted to further validate these findings.

4 June 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
CLChen Li
Chen Li
CLChun-Hua Liu
Chun-Hua Liu
YLYi-Fan Li
Yi-Fan Li
HHHui-Min Hu
Hui-Min Hu
QSQing Shi
Qing Shi
BFBi-Fa Fan
Bi-Fa Fan
Background: Diabetic peripheral neuropathic pain (DPNP), affecting ~50% of diabetes patients, imposes major burdens on quality of life and healthcare systems, while current therapies including pharmacotherapy and conventional spinal cord stimulation remain limited by insufficient efficacy and adverse effects. Our study aims to evaluate the clinical efficacy and safety of 10 kHz high-frequency spinal cord stimulation (HF-SCS) compared to traditional low-frequency SCS (T-SCS) in alleviating DPNP.Methods: This prospective, randomized, controlled, multicenter trial will enroll 100 participants with DPNP. Patients aged 18–80 with chronic (≥6-month) lower limb pain will be randomly assigned to HF-SCS (10 kHz) vs. T-SCS (40–60 Hz). The primary outcome is the treatment efficacy rate, defined as ≥50% reduction in numeric rating scale (NRS) scores at 3 months post-intervention. Secondary outcomes include improvements in quality of life (Short Form 12), sleep quality (Athens Insomnia Scale), psychological status (Beck Depression Inventory), neuropathy severity (Michigan Neuropathy Screening Instrument), and microcirculatory parameters assessed via infrared thermography. Safety evaluations encompass adverse events, laboratory tests, and imaging findings.Discussion: This study seeks to provide robust evidence on the superiority of HF-SCS in pain relief, functional improvement, and microcirculatory benefits, potentially establishing it as a preferred neuromodulation strategy for DPNP. Findings may advance clinical practice by addressing unmet needs in chronic pain management through targeted, mechanism-driven interventions.Clinical trial registration: https://www.chictr.org.cn/indexEN.html, identifier: ChiCTR2300078291.